| __timestamp | Exelixis, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2043000 | 21226345 |
| Thursday, January 1, 2015 | 3895000 | 139626 |
| Friday, January 1, 2016 | 6552000 | 93831530 |
| Sunday, January 1, 2017 | 15066000 | 79419009 |
| Monday, January 1, 2018 | 26348000 | 368673 |
| Tuesday, January 1, 2019 | 33097000 | 477121 |
| Wednesday, January 1, 2020 | 36272000 | 1895029 |
| Friday, January 1, 2021 | 52873000 | 8034589 |
| Saturday, January 1, 2022 | 57909000 | 20443000 |
| Sunday, January 1, 2023 | 72547000 | 33745000 |
| Monday, January 1, 2024 | 0 |
Unleashing the power of data
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue trends for Intra-Cellular Therapies, Inc. and Exelixis, Inc. from 2014 to 2023. Over this period, Exelixis, Inc. has seen a consistent rise in its cost of revenue, peaking in 2023 with a 3,450% increase from 2014. In contrast, Intra-Cellular Therapies, Inc. experienced a more volatile trajectory, with a significant spike in 2016, marking a 340% increase from the previous year, followed by fluctuations. By 2023, their cost of revenue was approximately 60% lower than Exelixis, Inc. These trends highlight the differing operational strategies and market responses of these two companies, offering valuable insights for potential investors.
Cost of Revenue Trends: Johnson & Johnson vs Exelixis, Inc.
Cost Insights: Breaking Down AbbVie Inc. and Intra-Cellular Therapies, Inc.'s Expenses
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Grifols, S.A.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Exelixis, Inc. vs Pharming Group N.V.
Cost of Revenue: Key Insights for Exelixis, Inc. and Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Exelixis, Inc. and CRISPR Therapeutics AG
Cost Insights: Breaking Down Exelixis, Inc. and MorphoSys AG's Expenses
Cost Insights: Breaking Down Exelixis, Inc. and Wave Life Sciences Ltd.'s Expenses